Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$1.41
-$0.08(-11.92%)
At close: 4:00 PM EDT
$1.41
-$0.08(-11.92%)
Day’s Range― - ―
52-Week Range$0.62 - $9.58
Previous Close$0.67
Volume161.72K
Average Volume (3M)132.54K
Market Cap
$6.47M
Enterprise Value$3.89M
Total Cash (Recent Filing)$3.52M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Nov 17, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding6,658,193
10 Day Avg. Volume132,580
30 Day Avg. Volume132,544
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.63
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$6.00Price Target Upside325.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraging And CapitalizationMaterial deleveraging and positive equity provide a stronger capitalization base than in 2024. Lower debt can reduce fixed financial pressure and preserve more flexibility for research spending, although continued losses still weigh on overall financial resilience.
Clinical Pipeline DevelopmentA focused pipeline of fibroblast-derived therapies gives the company a defined long-term development strategy in chronic diseases. Progress through preclinical and clinical programs could create future commercial opportunities if candidates demonstrate safety and efficacy.
Near-Term Funding FlexibilityThe convertible debenture adds near-term cash to support ongoing operations and development activities. Its fixed conversion price and issuance limits can constrain immediate dilution, while scheduled repayment terms make the funding more structured than an unrestricted equity raise.
Bears Say
No Revenue And Expanding LossesThe absence of revenue and persistently large losses show that the business remains pre-commercial and has not yet established an operating earnings base. Losses far above earlier periods indicate substantial investment needs and limited evidence of near-term self-funding.
Persistent Cash BurnSustained negative operating and free cash flow means research and corporate activities consume cash rather than generate it. Combined with no revenue, this leaves operations dependent on additional financing and increases exposure to unfavorable funding terms over time.
Listing And Financing RiskThe Nasdaq delisting process creates a structural trading and liquidity risk while the company works to regain compliance. Continued private financings and approved warrant-related share issuance also point to reliance on capital markets and potential dilution.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.62 and its highest was $9.58 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $6.47M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 29 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Jul 31, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.93 by $0.27.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 6,658,193 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.93. Following the earnings report the stock price went up 12.857%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$6.00
▲(325.53% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―
Ownership Overview
97.77% Insiders
1.04% Mutual Funds
<0.01% Other Institutional Investors
0.24% Public Companies and
Individual Investors